Ipilimumab (Yervoy®) and Nivolumab (Opdivo®) are immunotherapy drugs that work by reactivating the body’s immune response to target and destroy cancer cells. The combination of these drugs is a Health Canada-approved treatment for patients with advanced kidney cancer.
In this trial, researchers will combine Nivolumab with several experimental immunotherapy drugs to see if they are more effective than Ipilimumab in combination.
- Relatlimab – Targets a new anti-cancer target called LAG-3
- BMS-986205 – Targets a new anti-cancer target called IDO1
- BMS-813160 – Targets a new anti-cancer target called CCR2/5
This study will investigate the safety and effectiveness of Nivolumab in combination with four other immunotherapy drugs.
Accordingly, you may be randomly enrolled on any one of four treatment groups:
- Nivolumab + Ipilimumab
- Nivolumab + Relatlimab
- Nivolumab + BMS-986205
- Nivolumab + BMS-813160
- Clear cell kidney cancer
- Cancer has spread or cannot be removed by surgery
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreR.S. McLaughlin Durham Regional Cancer Centre||Principal Investigator||LocationOshawa, ON||Trial StatusRecruiting|
|Hospital / Cancer CentrePrincess Margaret Centre | University Health Network||Principal InvestigatorDr Srikala Sridhar||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreJuravinski Cancer Centre | Hamilton Health Sciences Centre||Principal InvestigatorDr Sebastian Hotte||LocationHamilton, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreHôpital général juif | Jewish General Hospital||Principal InvestigatorDr Wilson H. Miller Jr||LocationMontréal, QC||Trial StatusRecruiting|
|Hospital / Cancer CentreHôpital Hôtel-Dieu de Québec - CHUQ||Principal InvestigatorDr Vincent Fradet||LocationQuébec, QC||Trial StatusRecruiting|